Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Cornea and External Disease > Long-term follow-up confirms durability of Descemet stripping only
  • Cornea and External Disease

Long-term follow-up confirms durability of Descemet stripping only

Ophthalmology 360

Results from a recent retrospective study including 26 eyes of 20 patients undergoing Descemet stripping only (DSO) between December 2015 and November 2022 demonstrated the durability of DSO, with up to 7 years follow up in some cases.

The study included participants with peripheral endothelial cell count (ECC) >1000 cells/mm2 and symptoms caused by central guttata who underwent a central circular 4-mm descemetorhexis using a reverse Sinskey hook and a pair of descemetorhexis forceps with a peeling technique. Best-corrected visual acuity (BCVA), central corneal thickness (CCT), and ECC measured centrally and at the periphery were measured before surgery and at last follow-up. The mean age was 73 ± 9 years, and the follow-up period was 23.7 ± 24.8 months.

Twenty-two eyes responded to DSO with 20 female eyes (91%) and 2 male eyes (9%). The mean postoperative BCVA improved from 0.3 ± 0.17 logMAR to 0.09 ± 0.13 logMAR. The mean postop CCT decreased from 588 ± 41 μm to 546 ± 50 μm, while the mean postop central ECC was 780 ± 257 cells/mm2 [484-1500]. Peripheral ECC decreased postop (1837 ± 407 cells/mm2 preop to 864 ± 340 cells/mm2 postop). Peripheral endothelial cell polymegathism was stable while the average peripheral endothelial cells polymorphism decreased postoperatively (63.1 ± 20.5% preop to 33% ± 25% postop).

Four eyes without improvement after DSO underwent Descemet membrane endothelial keratoplasty surgery. The preoperative trend was for nonresponders to have lower BCVA, higher CCT, more abnormal peripheral polymorphism, and polymegathism, the researchers noted.

Reference:
Rizk M, Dubois M, Elahi S, et al. Long-term follow-up of descemet stripping only: Data up to 7 years postoperatively. Cornea. Published online Dec 26, 2023. doi:10.1097/ICO.0000000000003449

Share

Related Content

  • Cornea and External Disease

Quiz: The impact of blepharitis and conjunctivitis on quality of life

  • Cornea and External Disease

Phase 3 trial of cenegermin-bkbj for PCED enrolls first US patient

  • Cornea and External Disease

Cornea specialists identify key clinical signs linked to microbial keratitis subtypes

Cornea Update: Corneal Dystrophies & Related Conditions with an Update on Genetic Assessment and Treatment
  • Cornea and External Disease

Preventing complications of superficial keratectomy

  • Conference Roundup

Phase 1/2 CLARA study shows AURN001 improves BCVA compared with standard of care for corneal endothelial dysfunction

  • Conference Roundup

Epioxa crosslinking system has positive outcomes at 30 months in patients with keratoconus

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon